Current status of nanoparticle-based imaging agents for early diagnosis of cancer and atherosclerosis

Gurusamy Saravanakumar, Kwang Meyung Kim, Hyung Park Jae, Kyehan Rhee, Ick Chan Kwon

Research output: Contribution to journalArticle

32 Citations (Scopus)

Abstract

Endothelium plays a vital role in various vascular functions, and its dysfunction is a key underlying process closely related to diverse array of diseases such as atherosclerosis and tumor. Therefore, early detection of endothelial dysfunction at the functional or molecular level is of high importance for effective therapy. Recent advances in nanotechnology and our understanding in cellular and molecular biology have provided various biomedical imaging modalities and nanosized multimodal imaging agents. Multimodal nanoparticles that encompass the targeting ligands and magnetic/optical imaging labels enable us to visualize the pathophysiological process of various diseases using multiple imaging techniques. To visualize the specific pathogenic process at the molecular level, the imaging probe needs to be surface-functionalized with specific affinity ligands such as monoclonal antibodies (mAb). Combining the functional imaging agents along with therapeutic drugs has great potential for effective early detection, accurate diagnosis, and treatment of disease. The current review will highlight the application of various nanoparticle-based imaging agents and their recent developments in diagnosing endothelium dysfunction with a special emphasis on atherosclerosis and cancer.

Original languageEnglish
Pages (from-to)20-35
Number of pages16
JournalJournal of Biomedical Nanotechnology
Volume5
Issue number1
DOIs
Publication statusPublished - 2009 Feb 1
Externally publishedYes

Fingerprint

Early Detection of Cancer
Nanoparticles
Atherosclerosis
Imaging techniques
Endothelium
Multimodal Imaging
Ligands
Nanotechnology
Molecular Imaging
Optical Imaging
Blood Vessels
Cell Biology
Molecular Biology
Neoplasms
Therapeutics
Monoclonal Antibodies
Cytology
Molecular biology
Monoclonal antibodies
Pharmaceutical Preparations

Keywords

  • Angiogenesis
  • Atherosclerosis
  • Bioimaging
  • Endothelial
  • Imaging probes
  • Nanoparticles

ASJC Scopus subject areas

  • Bioengineering
  • Biomedical Engineering
  • Materials Science(all)
  • Medicine (miscellaneous)
  • Pharmaceutical Science

Cite this

Current status of nanoparticle-based imaging agents for early diagnosis of cancer and atherosclerosis. / Saravanakumar, Gurusamy; Kim, Kwang Meyung; Jae, Hyung Park; Rhee, Kyehan; Kwon, Ick Chan.

In: Journal of Biomedical Nanotechnology, Vol. 5, No. 1, 01.02.2009, p. 20-35.

Research output: Contribution to journalArticle

Saravanakumar, Gurusamy ; Kim, Kwang Meyung ; Jae, Hyung Park ; Rhee, Kyehan ; Kwon, Ick Chan. / Current status of nanoparticle-based imaging agents for early diagnosis of cancer and atherosclerosis. In: Journal of Biomedical Nanotechnology. 2009 ; Vol. 5, No. 1. pp. 20-35.
@article{c9647d4555eb4127a338609f99313255,
title = "Current status of nanoparticle-based imaging agents for early diagnosis of cancer and atherosclerosis",
abstract = "Endothelium plays a vital role in various vascular functions, and its dysfunction is a key underlying process closely related to diverse array of diseases such as atherosclerosis and tumor. Therefore, early detection of endothelial dysfunction at the functional or molecular level is of high importance for effective therapy. Recent advances in nanotechnology and our understanding in cellular and molecular biology have provided various biomedical imaging modalities and nanosized multimodal imaging agents. Multimodal nanoparticles that encompass the targeting ligands and magnetic/optical imaging labels enable us to visualize the pathophysiological process of various diseases using multiple imaging techniques. To visualize the specific pathogenic process at the molecular level, the imaging probe needs to be surface-functionalized with specific affinity ligands such as monoclonal antibodies (mAb). Combining the functional imaging agents along with therapeutic drugs has great potential for effective early detection, accurate diagnosis, and treatment of disease. The current review will highlight the application of various nanoparticle-based imaging agents and their recent developments in diagnosing endothelium dysfunction with a special emphasis on atherosclerosis and cancer.",
keywords = "Angiogenesis, Atherosclerosis, Bioimaging, Endothelial, Imaging probes, Nanoparticles",
author = "Gurusamy Saravanakumar and Kim, {Kwang Meyung} and Jae, {Hyung Park} and Kyehan Rhee and Kwon, {Ick Chan}",
year = "2009",
month = "2",
day = "1",
doi = "10.1166/jbn.2009.030",
language = "English",
volume = "5",
pages = "20--35",
journal = "Journal of Biomedical Nanotechnology",
issn = "1550-7033",
publisher = "American Scientific Publishers",
number = "1",

}

TY - JOUR

T1 - Current status of nanoparticle-based imaging agents for early diagnosis of cancer and atherosclerosis

AU - Saravanakumar, Gurusamy

AU - Kim, Kwang Meyung

AU - Jae, Hyung Park

AU - Rhee, Kyehan

AU - Kwon, Ick Chan

PY - 2009/2/1

Y1 - 2009/2/1

N2 - Endothelium plays a vital role in various vascular functions, and its dysfunction is a key underlying process closely related to diverse array of diseases such as atherosclerosis and tumor. Therefore, early detection of endothelial dysfunction at the functional or molecular level is of high importance for effective therapy. Recent advances in nanotechnology and our understanding in cellular and molecular biology have provided various biomedical imaging modalities and nanosized multimodal imaging agents. Multimodal nanoparticles that encompass the targeting ligands and magnetic/optical imaging labels enable us to visualize the pathophysiological process of various diseases using multiple imaging techniques. To visualize the specific pathogenic process at the molecular level, the imaging probe needs to be surface-functionalized with specific affinity ligands such as monoclonal antibodies (mAb). Combining the functional imaging agents along with therapeutic drugs has great potential for effective early detection, accurate diagnosis, and treatment of disease. The current review will highlight the application of various nanoparticle-based imaging agents and their recent developments in diagnosing endothelium dysfunction with a special emphasis on atherosclerosis and cancer.

AB - Endothelium plays a vital role in various vascular functions, and its dysfunction is a key underlying process closely related to diverse array of diseases such as atherosclerosis and tumor. Therefore, early detection of endothelial dysfunction at the functional or molecular level is of high importance for effective therapy. Recent advances in nanotechnology and our understanding in cellular and molecular biology have provided various biomedical imaging modalities and nanosized multimodal imaging agents. Multimodal nanoparticles that encompass the targeting ligands and magnetic/optical imaging labels enable us to visualize the pathophysiological process of various diseases using multiple imaging techniques. To visualize the specific pathogenic process at the molecular level, the imaging probe needs to be surface-functionalized with specific affinity ligands such as monoclonal antibodies (mAb). Combining the functional imaging agents along with therapeutic drugs has great potential for effective early detection, accurate diagnosis, and treatment of disease. The current review will highlight the application of various nanoparticle-based imaging agents and their recent developments in diagnosing endothelium dysfunction with a special emphasis on atherosclerosis and cancer.

KW - Angiogenesis

KW - Atherosclerosis

KW - Bioimaging

KW - Endothelial

KW - Imaging probes

KW - Nanoparticles

UR - http://www.scopus.com/inward/record.url?scp=67649813881&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=67649813881&partnerID=8YFLogxK

U2 - 10.1166/jbn.2009.030

DO - 10.1166/jbn.2009.030

M3 - Article

C2 - 20055103

AN - SCOPUS:67649813881

VL - 5

SP - 20

EP - 35

JO - Journal of Biomedical Nanotechnology

JF - Journal of Biomedical Nanotechnology

SN - 1550-7033

IS - 1

ER -